Aditxt, Inc.
$0.35
▼
-11.72%
2026-04-21 05:05:01
www.aditxt.com
NCM: ADTX
Explore Aditxt, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$0.39 M
Current Price
$0.35
52W High / Low
$2,594.48 / $0.39
Stock P/E
—
Book Value
$-151.87
Dividend Yield
—
ROCE
-318.91%
ROE
-6.99%
Face Value
—
EPS
$-9,230.64
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
1.4
Debt / Equity
76.04
Current Ratio
0.31
Quick Ratio
0.31
Forward P/E
-0.04
Price / Sales
142.11
Enterprise Value
$-1.39 M
EV / EBITDA
0.07
EV / Revenue
-436.31
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ACADIA Pharmaceuticals Inc. | $22.09 | 9.63 | $3.77 B | — | 8.14% | 39.89% | $28.35 / $14.08 | $7.21 |
| 2. | CytoMed Therapeutics Limited | $1.02 | — | $12.07 M | — | -33.09% | -50.28% | $3.68 / $0.73 | $0.43 |
| 3. | Aardvark Therapeutics, Inc. | $5.65 | — | $114.1 M | — | -58.82% | -64.44% | $17.94 / $3.35 | $4.89 |
| 4. | Krystal Biotech, Inc. | $276.4 | 40.42 | $8.11 B | — | 13.1% | 18.91% | $298.3 / $122.8 | $41.78 |
| 5. | PepGen Inc. | $1.73 | — | $117.5 M | — | -58.05% | -67.39% | $7.8 / $1.01 | $2.14 |
| 6. | Jyong Biotech Ltd. | $2.31 | — | $185.51 M | — | 35.69% | 8.55% | $67 / $1.43 | $-0.31 |
| 7. | Elicio Therapeutics, Inc. | $12.2 | — | $224.43 M | — | -210.11% | 817.92% | $14.93 / $4.7 | $0.09 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -4.67 M | -3.14 M | -6.15 M | -5.61 M | -5.65 M | — |
| Net Profit | -4.7 M | -24.05 M | -7.26 M | -5.71 M | -5.23 M | — |
| EPS in Rs | -5.2 | -26.59 | -8.02 | -6.31 | -5.78 | -6,045.89 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0.13 M | 0.65 M | 0.93 M |
| Operating Profit | -19.57 M | -27.86 M | -26.06 M | -24.94 M |
| Net Profit | -41.71 M | -34.45 M | -32.38 M | -27.65 M |
| EPS in Rs | -46.12 | -38.08 | -35.8 | -30.57 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 16.52 M | 32.14 M | 44.58 M | 10.74 M |
| Total Liabilities | 12.56 M | 31.05 M | 28.53 M | 5.53 M |
| Equity | 5.61 M | 1.67 M | 16.06 M | 5.21 M |
| Current Assets | 3.82 M | 2 M | 6.91 M | 4.74 M |
| Current Liabilities | 12.22 M | 23.41 M | 25.89 M | 3.64 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -25.69 M | -16.76 M | -19.2 M | -22.39 M |
| Investing CF | -2.44 M | -5 M | -0.01 M | -0.24 M |
| Financing CF | 30.49 M | 22.5 M | 16.55 M | 17.53 M |
| Free CF | -25.7 M | -16.76 M | -19.22 M | -22.76 M |
| Capex | -0.01 M | — | -0.01 M | -0.37 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -79.23% | -30.9% | — | — |
| Earnings Growth % | -6.38% | -17.11% | — | — |
| Profit Margin % | -25709.21% | -5018.92% | -2961.28% | — |
| Operating Margin % | -20796.13% | -4039.58% | -2670.64% | — |
| Gross Margin % | -368.32% | -17.31% | 17.88% | — |
| EBITDA Margin % | -20180.74% | -3945.89% | -2659.04% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-03-09 | 1:0.125 |
| 2025-11-03 | 1:0.00884956 |
| 2025-03-17 | 1:0.004 |
| 2024-10-02 | 1:0.025 |
| 2023-08-18 | 1:0.025 |